Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Assets (2021 - 2026)

Nuvectis Pharma has reported Assets over the past 6 years, most recently at $25.4 million for Q1 2026.

  • Quarterly results put Assets at $25.4 million for Q1 2026, down 15.76% from a year ago — trailing twelve months through Mar 2026 was $25.4 million (down 15.76% YoY), and the annual figure for FY2025 was $31.7 million, up 70.41%.
  • Assets reached $25.4 million in Q1 2026 per NVCT's latest filing, down from $31.7 million in the prior quarter.
  • Across five years, Assets topped out at $35.6 million in Q3 2025 and bottomed at $14.2 million in Q2 2022.
  • Median Assets over the past 5 years was $20.4 million (2022), compared with a mean of $22.6 million.
  • The largest annual shift saw Assets skyrocketed 206.52% in 2022 before it fell 26.63% in 2024.
  • Over 5 years, Assets stood at $20.4 million in 2022, then fell by 5.98% to $19.2 million in 2023, then decreased by 3.01% to $18.6 million in 2024, then surged by 70.41% to $31.7 million in 2025, then dropped by 19.9% to $25.4 million in 2026.
  • Business Quant data shows Assets for NVCT at $25.4 million in Q1 2026, $31.7 million in Q4 2025, and $35.6 million in Q3 2025.